Noninvasive methods in evaluation of inflammatory bowel disease: where do we stand now? An update
- PMID: 20186307
- PMCID: PMC2827710
- DOI: 10.1590/S1807-59322010000200015
Noninvasive methods in evaluation of inflammatory bowel disease: where do we stand now? An update
Abstract
The inflammatory bowel diseases, consisting of Crohn's disease, ulcerative colitis and indeterminate colitis, are distinguished by idiopathic and chronic inflammation of the digestive tract. The distinction between inflammatory bowel diseases and functional bowel disorders, such as irritable bowel syndrome, can be complex because they often present with similar symptoms. Rapid and inexpensive noninvasive tests that are sensitive, specific and simple are needed to prevent patient discomfort, delay in diagnosis, and unnecessary costs. None of the current commercially available serological biomarker tests can be used as a stand-alone diagnostic in clinics. Instead, these are used as an adjunct to endoscopy in diagnosis and prognosis of the disease. Along these lines,, fecal lactoferrin and calprotectin tests seem to be one step further from other tests with larger number of studies, higher sensitivity and specificity and wider availability.
Keywords: Diagnosis; Fecal markers; Inflammatory bowel disease; Serology.
Similar articles
-
[Fecal lactoferrin in identifying and management of inflammatory bowel disease].Pol Merkur Lekarski. 2014 Jul;37(217):61-4. Pol Merkur Lekarski. 2014. PMID: 25154203 Review. Polish.
-
Noninvasive Testing for Mucosal Inflammation in Inflammatory Bowel Disease.Gastrointest Endosc Clin N Am. 2016 Oct;26(4):641-56. doi: 10.1016/j.giec.2016.06.005. Epub 2016 Aug 9. Gastrointest Endosc Clin N Am. 2016. PMID: 27633593 Review.
-
The use of fecal calprotectin and lactoferrin in patients with IBD. Review.Acta Gastroenterol Belg. 2013 Sep;76(3):322-8. Acta Gastroenterol Belg. 2013. PMID: 24261027 Review.
-
FECAL CALPROTECTIN: levels for the ethiological diagnosis in Brazilian patients with gastrointestinal symptoms.Arq Gastroenterol. 2015 Jan-Mar;52(1):50-4. doi: 10.1590/S0004-28032015000100011. Arq Gastroenterol. 2015. PMID: 26017083
-
Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.Am J Gastroenterol. 2008 Jan;103(1):162-9. doi: 10.1111/j.1572-0241.2007.01556.x. Epub 2007 Oct 4. Am J Gastroenterol. 2008. PMID: 17916108
Cited by
-
Alterations in diversity of the oral microbiome in pediatric inflammatory bowel disease.Inflamm Bowel Dis. 2012 May;18(5):935-42. doi: 10.1002/ibd.21874. Epub 2011 Oct 10. Inflamm Bowel Dis. 2012. PMID: 21987382 Free PMC article.
-
The Immunological Basis of Inflammatory Bowel Disease.Gastroenterol Res Pract. 2016;2016:2097274. doi: 10.1155/2016/2097274. Epub 2016 Dec 14. Gastroenterol Res Pract. 2016. PMID: 28070181 Free PMC article. Review.
-
Low Mass Blood Peptides Discriminative of Inflammatory Bowel Disease (IBD) Severity: A Quantitative Proteomic Perspective.Mol Cell Proteomics. 2016 Jan;15(1):256-65. doi: 10.1074/mcp.M115.055095. Epub 2015 Nov 3. Mol Cell Proteomics. 2016. PMID: 26530476 Free PMC article.
-
Diagnostic Procedures for Inflammatory Bowel Disease: Laboratory, Endoscopy, Pathology, Imaging, and Beyond.Diagnostics (Basel). 2024 Jun 28;14(13):1384. doi: 10.3390/diagnostics14131384. Diagnostics (Basel). 2024. PMID: 39001273 Free PMC article. Review.
-
Fecal Myeloperoxidase as a Biomarker for Inflammatory Bowel Disease.Cureus. 2017 Jan 31;9(1):e1004. doi: 10.7759/cureus.1004. Cureus. 2017. PMID: 28286723 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical